News

Scientific resource

21/02/2023

IBD Case study

Discover an example of a screening cascade developed by Oncodesign Services that led to the identification of preclinical candidates.

Congress

21/02/2023

Oncodesign Services Events in March 2023

Oncodesign is taking part in many events this March. Here is a short selection of where we are travelling over the next few weeks. Learn more here

10/02/2023

The International Day of Women and Girls in Science

We met with women employees of Oncodesign Services to talk their careers and their ambitions for a better valorization of women in Science. Learn more here

Blog

02/02/2023

Why do preclinical cancer models still fail in the clinic?

We at Oncodesign Services strive to develop alternative Preclinical Cancer Models to better suit your drug development. Read more about our solutions here.

News

19/01/2023

Oncodesign S.A. is now Oncodesign Services S.A.

Oncodesign Services is chane announced the change of name to Oncodesign Services and a new COMEX for 2023.

News

14/12/2022

Oncodesign Services looks to the future

As Oncodesign evolves into Oncodesign Services and begins its journey as an independent business, CEO Fabrice Viviani explains his hopes and plans for the company’s future

Blog

08/11/2022

Why studying the gut microbes could help to cure?

We explore the importance of Gut Microbes on our health by discussing five of those Gut-Organ Axis - brain, intestine, liver, lung, and skin. Read more here.

Press release

19/10/2022

ERES IV acquires a majority stake in Oncodesign Services

ERES IV, advised by Elyan Partners, acquires a majority stake in Oncodesign Services and will file an offer on the company’s remaining shares. Find out more

Press release

30/09/2022

The General Meeting of Oncodesign authorises the allocation of OPM

Each Oncodesign shareholder will receive one OPM share for one ONCODESIGN share held

Press release

28/09/2022

Euronext Paris authorises the listing of OPM shares

Oncodesign Precision Medicine (OPM) and Oncodesign announce that Euronext Paris S.A. has authorised the admission to listing on Euronext Access + market in Paris of OPM’s ordinary shares.